The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in under-resourced countries.
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma is often foregone in community cancer centers and academic centers.
An anti-PD-1 therapy significantly improves overall survival compared with chemotherapy in previously treated patients with advanced bladder cancer, according to a study presented at the Society for Immunotherapy of Cancer 2016 meeting.
The neutrophil-to-lymphocyte ratio may not be as reliable as previously believed at predicating cancer progression and which drugs will be the most effective.